论文部分内容阅读
目的探讨吉非替尼一线治疗非小细胞肺癌临床疗效。方法回顾2008年1月—2010年1月收治的非小细胞肺癌78例临床资料进行总结。结果有效率RR38.4%,疾病控制率DCR 76.9%,中位缓解时间(6.6±3.8)月。结论吉非替尼作为靶向化疗药物,对非小细胞肺癌患者,疗效较肯定,不良反应少,患者的耐受性良好好,明显提高患者的生活质量,延长生命。对不愿或不能耐受全身化疗的非小细胞肺癌,可作为一线治疗方案。
Objective To investigate the clinical efficacy of first-line gefitinib in the treatment of non-small cell lung cancer. Methods The clinical data of 78 patients with non-small cell lung cancer admitted from January 2008 to January 2010 were retrospectively reviewed. Results The effective rate was RR38.4%, the disease control rate was DCR 76.9%, and the median time to remission was (6.6 ± 3.8) months. Conclusion Gefitinib, as a targeted chemotherapeutic drug, has definite curative effect on patients with non-small cell lung cancer, less adverse reactions and good patient tolerance. It significantly improves patients’ quality of life and prolongs life. Non-small cell lung cancer that is unwilling or unable to tolerate systemic chemotherapy can be used as a first-line treatment.